France’s Saint‑Julien site adds a bioprocess development suite for upstream/downstream scale-up of recombinant proteins, including complex mAbs and ADCs, and doubles bioconjugation capacity. Rodano, ...

Wilmington PharmaTech, a CRDMO that specializes in complex custom active pharmaceutical ingredients (API) for small molecules ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug ...

Wilmington PharmaTech ("Wilmington"), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex custom small-molecule API production, today announced a $50 ...

BOCA RATON, Fla.-- (BUSINESS WIRE)--March 19, 2026-- ...

Cambrex is expanding US and European operations with major investments in Iowa and Milan, boosting API capacity and R and D ...

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO).

India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...